Health groups irked by Supreme Court order on vaccine PSUs; mull fresh petition

on behalf of the All India Drug Action Network (AIDAN) and co-petitioners

19 February 2018

Several health groups expressed their strong disappointment with the order of the Supreme Court (SC) of February 12, 2018, which refused to review or recall an earlier order disposing off a case against the mala fide suspension of the vaccine Public Sector Units (PSUs) and government’s tendency to pamper private sector with public money.

The court relied only on the Government’s claims regarding the revival and modernization of the suspended PSUs and did not take into account the last rejoinder of the petitioners that highlighted the increasing diversion of purchase orders to private sector at ever increasing prices. The groups are considering filing a fresh petition, as the court also said “in case there is any deficiency or neglect on the part of the Government…, the petitioner shall be free to seek appropriate redress in appropriate proceedings at the appropriate stage.” Continue reading

Advertisements
Posted in Generics, Uncategorized | Leave a comment

The scalpels are out ahead of ‘Special 301’ Report

 by PT Jyothi Datta | The HinduBusinessLine

Indian pharma pushes back against US trade body’s criticism of its IPR protection record

For the past five years, a lone Indian pharmaceutical representation goes out to the Office of the US Trade Representative (USTR) every February to explain the lay of the land in respect of intellectual property rights (IPR).

The annual exercise precedes the release of the USTR’s ‘Special 301 Report’, which evaluates trading partners’ track record in implementing IPR. The IP report-card will be out late in April, but submissions to the USTR concluded last week. Continue reading

Posted in IPR, Special 301 report, Uncategorized | Leave a comment

How Meaningful Is India’s Improved Ranking On Intellectual Property Index?

By Payaswini Upadhyay, Source: BloombergQuint | February 12, 2018

India’s ranking improved among 50 countries in the annual International IP Index this year on better protection for trademarks and copyrights and easier rules to patent computer-related innovations.

The U.S. Chamber of Commerce Global Innovation Policy Center ranks countries annually based on their patent, trademark, copyright, and trade secrets protection policies. India’s rank on the sixth edition of index—44th of 50 economies compared with 43rd of 45 a year ago— has improved both in relative and absolute terms, Patrick Kilbride, vice-president of GIPC, told BloombergQuint in an emailed interview.

Continue reading

Posted in IPR, Uncategorized | Leave a comment

Malaysia drops four spots to 23rd place in global IP protection

Source: The Edge Markets

KUALA LUMPUR: Malaysia dropped four spots to 23rd place in the sixth annual US Chamber International Intellectual Property Index following an episode of compulsory licensing related to a medicine in 2017, which was seen as a negative development for its intellectual property (IP) landscape.

Malaysia was among 50 countries ranked in the latest index by the chamber’s Global Innovation Policy Center, with 19.47 points out of 40 indicators benchmarking patent, trademark, copyright, and trade secrets protection for an overall score of 48.7%. Continue reading

Posted in IPR, Uncategorized | Leave a comment

India’s Global Intellectual Property Index Ranking Improves, Climbs to 44 out of 50

Source: IANS Published: IndiaWest

NEW DELHI — India has substantially improved its ranking, to 44, in the latest Global Intellectual Property Index released by the U.S. Chambers of Commerce Feb. 8.

According to the annual report by the Global Innovation Policy Center of the U.S. Chambers of Commerce released in Washington, India has “increased substantially” its score in the latest Intellectual Property index with a rank of 44 out of 50 countries.  Continue reading

Posted in IPR, Uncategorized | Leave a comment

MSF Challenges Pfizer’s Monopoly on Lifesaving Pneumonia Vaccine in Korea

Doctors Without Borders urges Pfizer to drop unmerited patents that hinder access to lifesaving childhood vaccine worldwide

 NEW YORK/SEOUL, FEBRUARY 6, 2018—The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) is in the process of submitting a legal petition to the Supreme Court of South Korea requesting to review the patent granted to US pharmaceutical corporation Pfizer for its pneumococcal conjugate vaccine (PCV). On November 29, 2017, the Patent Court of Korea upheld the patent granted to Pfizer for its PCV13 product, marketed as Prevnar13. Unmerited patents like this are a barrier for people, governments, and treatment providers like MSF trying to protect children against pneumonia—a disease that kills almost one million kids every year or 2,500 per day.

Continue reading

Posted in Patent, Patent Opposition, Uncategorized, Vaccines | Leave a comment

PhRMA is angered by Colombia’s move to cut prices for hepatitis C drugs

By Ed Silverman, StatNews

In the latest battle between drug makers and the Colombian government,  an industry trade group has asked the Colombian health minister to scrap a move that is designed to unilaterally lower the prices of hepatitis C drugs or, eventually, issue compulsory licenses.

The move comes after Colombian Health Minister Alejandro Gaviria last month issued a resolution to determine whether a so-called declaration of public interest should be pursued, a step needed to lower prices. In a letter sent to the minister on Monday, the Pharmaceutical Research and Manufacturers of America argued the resolution is “legally and procedurally deficient,” and should be revoked. Continue reading

Posted in Compulsory Licensing, Drug prices, Hepatitis C, Uncategorized | Leave a comment